OFRM Q1 2026 Earnings EPS Falls Sharply Short of Estimates Revenue Unreported Atea Pharmaceuticals Q1 2026 Earnings Narrower Loss Surprises Analysts Amid RD Progress TFIN Q1 2026 Earnings Strong EPS Beat Despite Limited Revenue Disclosure OLLI Q1 2026 Earnings EPS Slightly Misses Estimates as Stock Dips BUSEP Q1 2026 Earnings 132 EPS Surprise Boosted by Solid Core Operations Processa Pharmaceuticals Inc PCSA Q4 2025 Earnings EPS Misses Estimates as Biotech Focuses on Clinical Pipeline